Sydney Brehany, MD
Medical Oncologist / Hematologist
About Sydney Brehany, MD
Dr. Sydney Brehany joined Rocky Mountain Cancer Center in 2023. As a medical oncologist and hematologist, she is ready to stand by your side throughout your cancer journey. Although she is comfortable treating a wide variety of cancers and blood disorders, her special focus is on breast cancer and gynecologic cancers, such as ovarian, uterine, and cervical cancers.
Dr. Brehany has a unique interest in conditions that might run in families, like hereditary breast and ovarian cancer (HBOC) syndrome and Lynch syndrome. With her expertise in genetic cancer risk assessment, she can identify individuals at risk and guide them on steps to lower that risk for both the patient and their loved ones. She has particular experience with cancer prevention and early detection in patients at high risk for breast cancer.
Dr. Brehany regularly participates in multi-disciplinary tumor boards alongside radiologists, pathologists, surgical oncologists, and radiation oncologists. She strongly believes cancer care is a team effort to bring patients the most up-to-date and comprehensive treatment plans possible.
Medical Oncology (Pending)
Medical Oncology & Hematology, University of Colorado Hospital, Aurora, CO
Internal Medicine, University of Colorado Hospital, Aurora, CO
Creighton University School of Medicine, Omaha, NE
Patient Care Philosophy
I truly value the relationships I build with each patient and their loved ones, especially as we confront cancer together. My objective is to ensure you grasp every aspect of your condition, so that collectively, we can create the most fitting treatment plan for your individual circumstances. Through collaborative decision-making, we’ll navigate this journey side by side, while focusing on your personal goals and preferences.
American Society of Clinical Oncology
American Society of Hematology
Clinical Cancer Genomics Community of Practice, City of Hope National Medical Center
Marsh S, Borges VF, Coons HL, Afghahi A. (2020). Sexual health after a breast cancer diagnosis in young women: implications for patients and providers. Breast Cancer Res Treat, 184(3):655-663.
Marsh S and Jimeno A. (2020). Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors. Drugs of Today, 56(6): 377-387.
Marsh S, Walters RW, Silberstein PT. (2018). Survival outcomes of radical prostatectomy versus radiotherapy in intermediate-risk prostate cancer: A NCDB study. Clin Genitourin Cancer, 16(1), e39-46. DOI: https://doi.org/10.1016/j.clgc.2017.07.029.
Marsh S, Wang J. (2017). Complete Remission of Liver and Bone Metastases After Nivolumab Treatment in a Patient with Renal Cell Carcinoma: The Potential Implication of MLH1 Mutations. Oncol Cancer Case Rep 3:125. doi: 10.4172/2471-8556.1000125
Marsh, S., Ratnaraj, F., Norris, R., Gass, J., Vivekanandan, R. (2017). Nocardia Mastoiditis in an Immunocompromised Patient. J Infect Dis Epidemiol, 3(2). DOI 10.23937/2474-3658/1510033.
Millis, S.Z., Marsh, S., Pecci, C., Boddupalli, S., Ross, J.S., Stephens, P., Miller, V.A., Ali, S.M., Wang, J. (2017). Identification of novel fumarate hydratase gene alterations in prostate cancer. Journal of Clinical Oncology 35, (suppl; abstr 11585).
Marsh, S. & Guck, T.P. (2016). Impact and Management of Psychological Comorbidities in Patients With COPD. Journal of Family Practice, 65(4):246-249, 255-256.
Lizalek, J., Mckenna, T., Huegel, K., Marsh, S., Carolan, A., Kobliska, A., … Ellerbroek, S.M. (2015). Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. Anticancer Research, 35(10):5263-5270.
Brehany, S., Colton, M., Duarte, C., Baliton, M., Okuyama-Sasaki, S. Hereditary cancer screening at an urban safety net hospital. J Clin Oncol 40, 2022 (suppl 16; abstr 10604).Presented at the 2022 American Society of Clinical Oncology Annual Meeting. Chicago, IL.
Buchanan, C., Caruso, C., Li, N., Shea, S., Beeson, A., Coulter, J., Duarte, C., Guinn, K., Herner, M., Hyson, P., Johnson, T., Johnson, M., Marsh, S., Anstett, T., Blum, J., Kulasekeran, V., & Porter, S. (2020). Expanding Addiction Treatment: A Residency-wide initiative to create Suboxone care pathways in resident continuity clinic. University of Colorado Quality and Safety Symposium. Aurora, CO. Accepted; meeting cancelled due to COVID-19 crisis.
Patil T, Mushtaq RR, Marsh S, Azelby C, Pujara M, Aisner D, Purcell WT, Schenk EL, Bunn PA, Pacheco JM, Camidge DR, Doebele RC. (2019). Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study [abstract]. In: Proceedings of 2019 American Society of Clinical Oncology; 2019 May 31 - June 4; Chicago, IL. Abstract 9090.
Malouff, T., Mathy, N.W., Marsh, S., Walters, R.W., Silberstein, P.T. (2017). Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database. Prostate Cancer Prostatic Dis, 20:334-338.
Ahmed, A., Malouff, T., Walters, R., Marsh, S., & Silberstein, P. (2017, February). Impact of income in stage IV prostate cancer. Presented at the 2017 American Society of Clinical Oncology Genitourinary Cancers Symposium. Orlando, FL.
Maldonado, E., Malouff, T.D, Marsh, S. & Silberstein, P.T. (2016). Impact of location on survival in prostate cancer. Journal of Clinical Oncology, 34 (suppl; abstr e16590).
Marsh, S., Ratnaraj, F., Norris, R., Gass, J. & Vivenkanandan, R. (2016, October). Nocardia Mastoiditis in an Immunocompromised Patient with Recurrent Otitis Media. Presented at Nebraska American College of Physicians Annual Meeting, Omaha, NE.
Marsh, S., Walters, R.W. & Silberstein P.T. (2016, June). Overall survival in stage II prostate cancer after radiation or surgical therapy. Journal of Clinical Oncology 34, (suppl; abstr 5068). Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Malouff, T.D., Marsh, S. & Silberstein, P.T. (2016, June). Effect of radiotherapy treatment modalities on survival in stage IIa prostate cancer: A National Cancer Data Base (NCDB) analysis. Journal of Clinical Oncology 34, (suppl; abstr 5069). Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Malouff, T., Marsh, S., Walters, R. & Silberstein, P. (2016, September). Trends in the Use of Radiation Therapy for Stage IIA Prostate Cancer from 2004-2013: A Retrospective Analysis Using the National Cancer Data Base (NCDB). Presented at the 58th American Society for Radiation Oncology Annual Meeting, Boston, MA.
Malouff, T., Marsh, S., Walters, R. & Silberstein, P. (2016, September). Long-term Survival by Method of Brachytherapy in Stage IIA Prostate Cancer: A National Cancer Data Base (NCDB) Analysis. Presented at the 58th American Society for Radiation Oncology Annual Meeting. Boston, MA.
Malouff T., Marsh S. & Silberstein P. (2016, April). Trends in the Use of Radiation Therapy for Stage IIA Prostate Cancer by Population Size. Presented at St. Albert’s Day, Creighton University, Omaha NE.
Wu, J., Marsh, S., Peterson, D., Buri, M., Wilkerson, E., Ellison, T., … VanGalder, H. (2016, February). Creighton University School of Medicine Advocates: Medical student advocacy for diverse health care needs in the Omaha community. Presented at the Global Health Conference Midwest: Bridging Borders at Home and Abroad, Omaha, NE.
Malouff, T., Walters, R., Marsh, S. & Silberstein, P. (2016, September). Comparison of External Beam Radiation Therapy (EBRT) Techniques on Survival in Stage IIA Prostate Cancer. Presented at the 58th American Society for Radiation Oncology Annual Meeting. Boston, MA.